Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2014; 20(1): 64-77
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.64
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.64
Inflammatory pathways of importance for management of inflammatory bowel disease
Jannie Pedersen, Mehmet Coskun, Christoffer Soendergaard, Mohammad Salem, Ole Haagen Nielsen, Department of Gastroenterology, Medical Section, University of Copenhagen, Herlev Hospital, DK-2730 Herlev, Denmark
Mehmet Coskun, Department of Cellular and Molecular Medicine, the Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark
Author contributions: Pedersen J analyzed the literature, wrote the 1st manuscript draft, and wrote the final revision of the article; Soendergaard C and Salem M provided intellectual input, advice, and contributed to the writing and final revision of the manuscript; Coskun M and Nielsen OH contributed to the conceptual design, drafting of the manuscript and revising it critically for important intellectual content; all authors contributed to the writing and all authors approved the final submitted manuscript.
Supported by Grants from the Foundation of Aase and Ejnar Danielsen, the Foundation of Axel Muusfeldt, and the A P Møller Foundation (“Fonden til Lægevidenskabens Fremme”)
Correspondence to: Mehmet Coskun, PhD, Department of Gastroenterology, Medical Section, University of Copenhagen, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. mehmet.coskun@regionh.dk
Telephone: +45-38-683421 Fax: +45-38-684009
Received: September 19, 2013
Revised: November 5, 2013
Accepted: December 3, 2013
Published online: January 7, 2014
Revised: November 5, 2013
Accepted: December 3, 2013
Published online: January 7, 2014
Core Tip
Core tip: Crohn’s disease and ulcerative colitis are the two prevailing forms of inflammatory bowel disease (IBD). Both diseases are associated with an increased expression of pro-inflammatory cytokines and immune cell infiltration of the inflamed tissue. Current treatment options with tumor necrosis factor-α inhibitors are discussed. Additionally, new therapeutic strategies showing promising results, e.g., small pharmacologic inhibitors aimed at inhibiting Janus kinase pathway and antibodies blocking recruitment of immune cells to the site of inflammation are also discussed. In this review we have elucidated the major signaling pathways of clinical importance for new therapeutic strategies of IBD.